Brodalumub: also effective against Nail and Scalp Psoriasis
- Brodalumab (KHK4827, also known as AMG827) is a monoclonal antibody that binds to human IL-17RA and blocks the biological activities of IL-17A, 17F, 17A/F and IL-17E
- It has been shown to improve plaque psoriasis and psoriatic arthritis in 12 weeks.
Goal: efficacy of KHK4827 for nail nail and scalp psoriasis in Japanese patients with moderate to severe plaque psoriasis.
- RCT with 70,140 or 210mg every 2 weeks vs placebo
- Evaluation (0 vs 12 weeks): PSSI (scalp) and NAPSI (nails) scores, DLQI, rheumatology (ACR) scores
- 1551 patients were enrolled: 4 discontinued in the placebo group and 2 in the treated group (70mg dosage, adverse effect)19 patients had psoriatric arthritis
- NAPSI reduced at week 12: -9.6% (placebo), -9.1% (70mg), -44.9% (140mg) and -47.3% (210mg)
- PSSI reduced at week -12.6% (placebo), -38.3% (70mg), -73.8% (70mg) and -94.5% (210mg)
- ACR 20 improvement at week 12 was seen in treated individuals: 0% (placebo), 20% (70mg), 40% (140mg) and 100% (210mg)
- DLQI reduced significantly. DLQI was 0 or 1 at week 12 in 9% (Placebo), 27% (70mg), 54% (140mg) and 57% (210mg) of patients respectively.
Conclusion: Brodalumab is not only effective in plaque psoriasis but also in nail and scalp psoriasis. Conclusions for nail psoriasis treatment response cannot be drawn from this study because of the small sample size.
Dr Christophe Hsu – dermatologist. Geneva, Switzerland
Source of information: p1566 A novel biological agent brodalumab (KHK4827) was effective for nail nail and scalp psoriasis and inproves patient’s quality of life. Umezawa Y. et al. EADV Annual Meeting (2014), Amsterdam The Netherlands